SCI Abstract

search
+
Clinical course and management of pembrolizumab-associated isolated adrenocorticotrophic hormone deficiency: a new case and literature review
Hypophysitis is rarely reported in patients receiving pembrolizumab-only immunotherapies. Since the clinical presentation ...
Atherosclerosis: immunopathogenesis and strategies for immunotherapy
Atherosclerosis, a chronic inflammatory condition in which atheroma accumulates within the intima of the arterial wall, is...
Anti-PD-1 and regorafenib induce severe multisystem adverse events in microsatellite stability metastatic colorectal cancer: a case report
There exists a dilemma in the treatment of microsatellite stability (MSS) metastatic colorectal cancer (mCRC) owing to lim...
Durable response after immune checkpoint inhibitor-related diabetes in mismatch repair deficient pancreatic cancer
Mismatch repair protein deficiency occurs in 0.8–2% of pancreatic ductal adenocarcinomas and confers susceptibility to imm...
Real-world treatment patterns and outcomes in PD-L1-positive non-small cell lung cancer
Aim: We report real-world treatment patterns and outcomes in patients with PD-L1+ non-small cell lung cancer (NSCLC). Meth...
Patient needs and benefits of sublingual immunotherapy for grass pollen-induced allergic rhinitis: an observational study
Aim: Clinical efficacy of sublingual immunotherapy for grass pollen-induced allergic rhinitis (AR) needs to translate into...
Pretreatment lung immune prognostic index as a biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumab
Background: To investigate the role of pretreatment lung immune prognostic index (LIPI) as biomarker in PD-L1 ≥50% non-sma...
Delayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review
Aim: Cytokine release syndrome (CRS) is an infrequently described immune-related adverse event of checkpoint inhibitors (C...
format_indent_increase